Investigating how BOK protein affects cell death in Alzheimer's disease
Official title: Cell Death Regulation by Pro-Apoptotic BOK in Tauopathies
Funded at Yale University · NIH-10978687 · Data updated 2026-11-12
This study is looking at a protein called BOK to see how it affects cell death in Alzheimer's and similar diseases, with the hope of finding new ways to help protect brain cells and improve treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,969,620 |
| NIH project number | 1RF1NS126251-01A1 |
| Project ID | NIH-10978687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies.
✕Less likely to help
Patients with non-tauopathies or other forms of dementia unrelated to tau protein may not benefit from this research.
What this research studies
This research focuses on understanding the role of the BOK protein in the process of cell death associated with Alzheimer's disease and other tauopathies. By examining how BOK interacts with cellular structures involved in calcium signaling and stress responses, the study aims to uncover the mechanisms that lead to neuron loss in these conditions. The researchers will explore how BOK influences metabolic pathways and neuronal survival, potentially identifying new therapeutic targets for treatment. Patients may benefit from insights gained into how to prevent or mitigate neurodegeneration linked to tau protein accumulation.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent neuron loss in Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in targeting cell death pathways in neurodegenerative diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Katz, Samuel G — Yale University
- Study coordinator: Katz, Samuel G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.